Director at YD Bio (YDES) receives $60K RSU equity award

Rhea-AI Filing Summary

YD Bio Ltd director Chang Kochi reported equity compensation activity involving restricted share units. On March 31, 2026, Kochi received 2,081 restricted share units, each representing a right to one ordinary share.

The same day, 2,081 RSUs were exercised and converted into 2,081 ordinary shares at a price of $0.0000 per share, leaving 2,081 ordinary shares held directly after the transactions. The award was granted under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments of $15,000 each based on a seven trading-day volume-weighted average price.

Insider Trade Summary

2,081 shares exercised/converted

Mixed 3 txns

Insider Chang Kochi

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	2,081	$0.00	--
Exercise	Restricted Share Units	2,081	$0.00	--
Exercise	Ordinary Shares	2,081	$0.00	--

Holdings After Transaction: Restricted Share Units — 2,081 shares (Direct); Ordinary Shares — 2,081 shares (Direct)

Footnotes (1)

1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting. The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").

Key Figures

RSUs granted: 2,081 restricted share units Shares acquired: 2,081 ordinary shares Grant date fair value: $60,000 +4 more

7 metrics

RSUs granted 2,081 restricted share units Grant on March 31, 2026

Shares acquired 2,081 ordinary shares RSU exercise/conversion on March 31, 2026

Grant date fair value $60,000 Aggregate target grant date fair value of RSUs

Quarterly vesting tranche $15,000 per installment Four equal quarterly installments beginning March 31, 2026

Par value per share $0.0001 per ordinary share Ordinary shares underlying the RSUs

VWAP period 7 trading days Volume-weighted average price used to determine RSUs vesting

Exercises reported 1 derivative exercise, 2,081 shares transactionSummary exerciseCount and exerciseShares

Key Terms

Restricted Share Units, Equity Incentive Plan, volume-weighted average price, par value, +1 more

5 terms

Restricted Share Units financial

"Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Equity Incentive Plan financial

"The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

volume-weighted average price financial

"dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

par value financial

"one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

Ordinary Shares financial

"one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chang Kochi

(Last) (First) (Middle)

C/O YD BIO LIMITED

12F., NO. 3, XINGNAN ST., NANGANG DIST.

(Street)

TAIPEI CITY 115001

(City) (State) (Zip)

TAIWAN

(Country)

2. Issuer Name and Ticker or Trading Symbol
YD Bio Ltd [ YDES ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/31/2026		M		2,081	A	(1)	2,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	03/31/2026		A		2,081(2)(3)		(2)	(2)	Ordinary Shares	2,081	$0	2,081	D
Restricted Share Units	(1)	03/31/2026		M		2,081		(2)	(2)	Ordinary Shares	2,081	$0	0	D

Explanation of Responses:

1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.

2. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.

3. The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").

	/s/ Kochi Chang	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did YDES director Chang Kochi report?

Chang Kochi reported an equity compensation event involving 2,081 restricted share units that converted into 2,081 ordinary shares on March 31, 2026. The RSUs were granted and exercised at $0.0000 per share as part of YD Bio Limited’s equity incentive compensation.

How many YD Bio (YDES) shares did Chang Kochi acquire in this Form 4?

Chang Kochi effectively acquired 2,081 ordinary shares of YD Bio Ltd through the exercise of 2,081 restricted share units on March 31, 2026. After the transactions, the Form 4 shows direct ownership of 2,081 ordinary shares tied to this compensation event.

What is the value of the RSU award reported for YD Bio (YDES)?

The restricted share unit award has an aggregate target grant date fair value of $60,000 as of March 31, 2026. This value is structured to vest in four equal quarterly installments of $15,000 each, determined using a seven trading-day volume-weighted average price.

How do the YD Bio (YDES) RSUs granted to Chang Kochi vest?

The RSUs vest in four equal quarterly installments beginning on March 31, 2026, with each installment targeting $15,000 in value. The number of RSUs vesting each quarter is calculated by dividing $15,000 by the seven trading-day volume-weighted average price of YD Bio’s ordinary shares.

What does each YD Bio (YDES) restricted share unit represent?

Each restricted share unit represents a contingent right to receive one ordinary share of YD Bio Ltd with a par value of $0.0001 per share. When RSUs vest and are exercised, they convert into ordinary shares, as shown by the 2,081 RSUs converting into 2,081 shares.